Arcutis Biotherapeutics Return on Equity

Arcutis Biotherapeutics (ARQT) currently reports a ROE of -1.25%. That is below the Healthcare sector average of 29.39%. Use the charts on this page to explore Arcutis Biotherapeutics's ROE history and peer comparisons.

Arcutis Biotherapeutics's ROE of -1.25% is lower than the Healthcare sector average of 29.39%. That is roughly 104.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Arcutis Biotherapeutics's current -1.25% should be judged against Healthcare norms (sector average: 29.39%) and against ARQT's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -1.25%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 29.39%. From there, open related valuation or income-statement pages for Arcutis Biotherapeutics, and consider following ARQT for alerts when major investors trade the stock.

Arcutis Biotherapeutics is classified in the Healthcare sector. On ROE, it currently shows -1.25% versus a sector average near 29.39%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ARQT with unrelated industries.